Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) insider Mark James Litton sold 16,519 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at approximately $1,257,670.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark James Litton also recently made the following trade(s):

  • On Monday, October 16th, Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60.

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) traded down $0.70 on Wednesday, reaching $9.95. 1,908,700 shares of the company’s stock were exchanged, compared to its average volume of 1,143,325. Alder BioPharmaceuticals, Inc. has a 12-month low of $8.60 and a 12-month high of $34.30.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.29. During the same quarter last year, the business posted ($0.70) EPS. equities analysts forecast that Alder BioPharmaceuticals, Inc. will post -5.36 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/15/alder-biopharmaceuticals-inc-aldr-insider-mark-james-litton-sells-16519-shares.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantitative Systematic Strategies LLC acquired a new position in shares of Alder BioPharmaceuticals in the 3rd quarter valued at $132,000. Legal & General Group Plc grew its holdings in shares of Alder BioPharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 400 shares during the period. SG Americas Securities LLC grew its holdings in shares of Alder BioPharmaceuticals by 109.4% in the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 8,140 shares during the period. Jane Street Group LLC acquired a new position in shares of Alder BioPharmaceuticals in the 3rd quarter valued at $184,000. Finally, Voya Investment Management LLC grew its holdings in shares of Alder BioPharmaceuticals by 8.4% in the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,734 shares during the period. 78.93% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have commented on the stock. BidaskClub upgraded shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Zacks Investment Research cut shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $27.00 target price (down previously from $39.00) on shares of Alder BioPharmaceuticals in a research note on Wednesday, August 9th. Credit Suisse Group set a $11.00 target price on shares of Alder BioPharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 24th. Finally, Mizuho initiated coverage on shares of Alder BioPharmaceuticals in a research note on Wednesday, September 6th. They issued a “buy” rating and a $32.00 target price for the company. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. Alder BioPharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $28.07.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.